NO952884L - Spirocykloalkyl-substituerte azetidinoner som er anvendbare som hypokolesterolemiske midler - Google Patents
Spirocykloalkyl-substituerte azetidinoner som er anvendbare som hypokolesterolemiske midlerInfo
- Publication number
- NO952884L NO952884L NO952884A NO952884A NO952884L NO 952884 L NO952884 L NO 952884L NO 952884 A NO952884 A NO 952884A NO 952884 A NO952884 A NO 952884A NO 952884 L NO952884 L NO 952884L
- Authority
- NO
- Norway
- Prior art keywords
- optionally substituted
- lower alkyl
- alkenylene
- sum
- compounds
- Prior art date
Links
- 239000003529 anticholesteremic agent Substances 0.000 title abstract 2
- MNFORVFSTILPAW-UHFFFAOYSA-N azetidin-2-one Chemical class O=C1CCN1 MNFORVFSTILPAW-UHFFFAOYSA-N 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 7
- 150000001875 compounds Chemical class 0.000 abstract 5
- 125000004450 alkenylene group Chemical group 0.000 abstract 4
- 125000004432 carbon atom Chemical group C* 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 abstract 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 abstract 2
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 abstract 2
- 125000001624 naphthyl group Chemical group 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 235000012000 cholesterol Nutrition 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000002993 cycloalkylene group Chemical group 0.000 abstract 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/12—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Nye forbindelser av formel (1) l . uH-----f J---"N G ^ eller et farmasøytisk akseptabelt salt derav, hvori R, er (A) -CH-, -C (lavere alkyl)-, -CF-, -C(OH)-, -C(CgH5)-, -C(C6H4-ttJ5)-, -N- eller -+N0~ (A) i B-CH=C- (A1) R2 og R, er uavhengig valgt fra gruppen bestående av -CH2~, -CH(lavere alkyl)-, -C(di-lavere alkyl)-, -CH=CH- og -C(lavere alkyl) =CH-; eller R, sammen med en til- støtende R2, eller R, sammen med en tilstøtende R.,, danner en -CH=CH- eller en -CH=C(lavere alkyl)-gruppe; u og v er uavhengig O, l, 2 eller 3, forutsatt at begge ikke er null; forutsatt at når R2 er -CH=CH- eller -C(lavere alkyl)=CH-, er v 1; forutsatt at når R., er -CH=CH- eller -Cdavere alkyl)=CH-, er u 1; forutsatt at når v er 2 eller 3, kan R-, være like eller forskjellige; og forutsatt at når u er 2 eller 3, kan R- være like eller forskjellige; R4 er B-(CH2)mC(0)-, hvori m er 0-5; B-"(CH2)q-, hvori q er 0-6; B-(CH2>e- Z-(CH2)-, hvori Z er -O-, -C(O)-, fenylen, -N(Rg)- eller -S(O)Q_2-, e er 0-5 og r er 0-5, forutsatt at summen av e og r er 0-6; B-(C2~Cg- alkenylen)-, B-(C4-Cg-alkadienylen)-; B-(CH2) -Z-(C2-Cg-alkenylen)-, hvori t er 0-3, forutsatt at summen av t og antallet av carbonatomer i alke- nylenkjeden er 2-6; B-(CH2)f-V-(CH2) - hvori V er C,-C4~cykloalkylen, f er 1-5 og g er 0-5, forutsatt at summen av f og g er 1-6; B-(CH2)fc-V-(C2~Cg- alkenylen)- eller B'-<C2-C,-alkenylen)- V-(CH-).- forutsatt at summen av t og 2 t 3 antallet av carbonatomer i alkenylen- kjeden er 2, 3, 4, 5 eller 6; B-(CH2)a-Z-(CH2)b-V-(CH2)d-, hvori a, b og d er uavhengig 0-6, forutsatt at summen av a, b og d er 0-6; T-(CH2) -, hvori T er cykloalkyl med 3-6 carbon- atomer og s er 0-6; eller R, og R. danner sammen gruppen (A1); B er eventuelt substituert fenyl, indanyl, indenyl, nafthyl, tetrahydronafthyl eller eventuelt substituert hetero- aryl; og R_Q og R2, er uavhengig eventuelt substituert fenyl, eventuelt substituert nafthyl, indanyl, indenyl, tetrahydronafthyl, benzodioxolyl, eventuelt substituert heteroaryl, eventuelt substituert benzokondensert heteroaryl eller cyklopropyl, er be- skrevet, samt. farmasøytiske preparater omfattende angitte forbindelser, anvendelse av angitte forbindelser som hypokolesterolemiske midler, fremgangs- måter for fremstilling av forbindelsene og anvendelse av angitte forbindelser i kombinasjon med kolesterolbiosyntesein- hibitorer for å behandle eller forhindre atherosklerose.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US643993A | 1993-01-21 | 1993-01-21 | |
| PCT/US1994/000421 WO1994017038A1 (en) | 1993-01-21 | 1994-01-19 | Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO952884D0 NO952884D0 (no) | 1995-07-20 |
| NO952884L true NO952884L (no) | 1995-09-20 |
Family
ID=21720894
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO952884A NO952884L (no) | 1993-01-21 | 1995-07-20 | Spirocykloalkyl-substituerte azetidinoner som er anvendbare som hypokolesterolemiske midler |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US5698548A (no) |
| EP (1) | EP0681569B1 (no) |
| JP (1) | JP2719445B2 (no) |
| KR (1) | KR960700227A (no) |
| CN (1) | CN1118163A (no) |
| AT (1) | ATE199899T1 (no) |
| AU (1) | AU683048B2 (no) |
| CA (1) | CA2154257C (no) |
| CZ (1) | CZ180195A3 (no) |
| DE (1) | DE69426924T2 (no) |
| DK (1) | DK0681569T3 (no) |
| EE (1) | EE9400394A (no) |
| ES (1) | ES2155849T3 (no) |
| FI (1) | FI953497A0 (no) |
| GR (1) | GR3035963T3 (no) |
| HU (1) | HUT72592A (no) |
| IL (1) | IL108368A0 (no) |
| LT (1) | LT3595B (no) |
| NO (1) | NO952884L (no) |
| NZ (1) | NZ261714A (no) |
| PL (1) | PL309978A1 (no) |
| PT (1) | PT681569E (no) |
| SI (1) | SI9400022A (no) |
| SK (1) | SK91195A3 (no) |
| WO (1) | WO1994017038A1 (no) |
| ZA (1) | ZA94386B (no) |
Families Citing this family (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0647234A1 (en) * | 1992-06-26 | 1995-04-12 | Pfizer Inc. | Steroidal glycosides for treating hypercholesterolemia |
| US5631365A (en) | 1993-09-21 | 1997-05-20 | Schering Corporation | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
| US5656624A (en) * | 1994-12-21 | 1997-08-12 | Schering Corporation | 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents |
| US5648484A (en) * | 1995-03-07 | 1997-07-15 | Schering Corporation | Catalytic enantioselective synthesis of a spriofused azetidinone |
| PT877750E (pt) | 1995-10-31 | 2002-09-30 | Schering Corp | 2-azetidinonas substituidas por acucar uteis como agentes hipocolesterolemiantes |
| US5756470A (en) * | 1996-10-29 | 1998-05-26 | Schering Corporation | Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents |
| WO2000063703A1 (en) | 1999-04-16 | 2000-10-26 | Schering Corporation | Use of azetidinone compounds |
| US6297268B1 (en) | 1999-11-30 | 2001-10-02 | Schering Corporation | Imidazoles as cholesterol lowering agents |
| US6982251B2 (en) | 2000-12-20 | 2006-01-03 | Schering Corporation | Substituted 2-azetidinones useful as hypocholesterolemic agents |
| RU2297422C2 (ru) * | 2000-12-20 | 2007-04-20 | Шеринг Корпорейшн | Замещенные остатком сахара 2-азетидиноны, пригодные для использования в качестве гипохолестеринемических препаратов |
| AU2005246926B2 (en) * | 2001-01-26 | 2008-02-28 | Merck Sharp & Dohme Corp. | The use of substituted azetidinone compounds for the treatment of sitosterolemia |
| IL156445A0 (en) | 2001-01-26 | 2004-01-04 | Schering Corp | Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications |
| EP1911462A3 (en) | 2001-01-26 | 2011-11-30 | Schering Corporation | Compositions comprising a sterol absorption inhibitor |
| SK9502003A3 (en) * | 2001-01-26 | 2003-12-02 | Schering Corp | Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions |
| US7071181B2 (en) | 2001-01-26 | 2006-07-04 | Schering Corporation | Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors |
| AR035533A1 (es) | 2001-01-26 | 2004-06-02 | Schering Corp | Uso de por lo menos un inhibidor de la absorcion de los esteroles o sus sales, solvatos, prodrogas farmaceuticamente aceptables o mezclas de los mismos para la preparacion de un medicamento para el tratamiento de la sitosterolemia, composiciones farmaceuticas, el uso de dichas composiciones para la |
| EE05453B1 (et) | 2001-03-28 | 2011-08-15 | Schering Corporation | Protsess asetidinoonvahehendite valmistamiseks |
| US7056906B2 (en) | 2001-09-21 | 2006-06-06 | Schering Corporation | Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women |
| US7053080B2 (en) | 2001-09-21 | 2006-05-30 | Schering Corporation | Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors |
| MXPA04002573A (es) | 2001-09-21 | 2004-06-18 | Schering Corp | Tratamiento de xantoma con derivados de azetidinona como inhibidores de la absorcion de esterol. |
| EP1859796A3 (en) * | 2001-09-21 | 2008-07-02 | Schering Corporation | Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors |
| US20030204096A1 (en) * | 2002-03-25 | 2003-10-30 | Schering Corporation | Enantioselective synthesis of azetidinone intermediate compounds |
| GB0215579D0 (en) | 2002-07-05 | 2002-08-14 | Astrazeneca Ab | Chemical compounds |
| US20040132058A1 (en) | 2002-07-19 | 2004-07-08 | Schering Corporation | NPC1L1 (NPC3) and methods of use thereof |
| US7135556B2 (en) * | 2002-07-19 | 2006-11-14 | Schering Corporation | NPC1L1 (NPC3) and methods of use thereof |
| AR040588A1 (es) * | 2002-07-26 | 2005-04-13 | Schering Corp | Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa |
| US6933292B2 (en) * | 2002-07-30 | 2005-08-23 | Children's Medical Center Corporation | Compositions of ezetimibe and methods for the treatment of cholesterol-associated benign and malignant tumors |
| WO2004043457A1 (en) | 2002-11-06 | 2004-05-27 | Schering Corporation | Cholesterol absorptions inhibitors for the treatment of autoimmune disorders |
| US7459442B2 (en) | 2003-03-07 | 2008-12-02 | Schering Corporation | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
| JP2006519869A (ja) | 2003-03-07 | 2006-08-31 | シェーリング コーポレイション | 置換アゼチジノン化合物、置換アゼチジノン化合物を調製するためのプロセス、それらの処方物および使用 |
| CA2517572C (en) | 2003-03-07 | 2011-12-13 | Schering Corporation | Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia |
| EP1601668B1 (en) | 2003-03-07 | 2008-08-27 | Schering Corporation | Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia |
| NZ543102A (en) | 2003-04-24 | 2008-12-24 | Incyte Corp | Aza spiro alkane derivatives as inhibitors of metalloproteases |
| JP2005015434A (ja) * | 2003-06-27 | 2005-01-20 | Kotobuki Seiyaku Kk | 血清コレステロール低下剤或はアテローム性硬化症の予防又は治療剤 |
| EP1918000A2 (en) | 2003-11-05 | 2008-05-07 | Schering Corporation | Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions |
| JP2007510659A (ja) * | 2003-11-05 | 2007-04-26 | シェーリング コーポレイション | 脂質調節剤および置換アゼチジノンの組み合わせならびに血管状態の処置 |
| EP1699759B1 (en) | 2003-12-23 | 2010-10-20 | AstraZeneca AB | Diphenylazetidinone derivates possessing cholesterol absorption inhibitory activity |
| CN100471835C (zh) * | 2003-12-23 | 2009-03-25 | 默克公司 | 抗高胆固醇血症化合物 |
| WO2005069900A2 (en) * | 2004-01-16 | 2005-08-04 | Merck & Co., Inc. | Npc1l1 (npc3) and methods of identifying ligands thereof |
| EP1598336A1 (en) * | 2004-05-20 | 2005-11-23 | Laboratorios Del Dr. Esteve, S.A. | Regioselective hydroxylation, functionalisation and protection of spirolactams |
| US7291728B2 (en) | 2004-05-10 | 2007-11-06 | Laboratories Del Dr. Esteve, S.A. | Spirolactams and their synthesis |
| EP1676836A1 (en) * | 2004-12-30 | 2006-07-05 | Laboratorios Del Dr. Esteve, S.A. | Regioselective hydroxylation, functionalisation and protection of spirolactams II |
| US20080045726A1 (en) * | 2004-05-10 | 2008-02-21 | Laboratorios Del Dr. Esteve, S.A. | Spirolactams and Their Synthesis |
| JP2007536329A (ja) * | 2004-05-10 | 2007-12-13 | ラボラトリオス・デル・ドクトル・エステベ・ソシエダッド・アノニマ | スピロラクタム類の位置選択的官能化および保護 |
| WO2006039334A1 (en) * | 2004-09-29 | 2006-04-13 | Schering Corporation | Combinations of substituted azetidonones and cb1 antagonists |
| CN101115726A (zh) | 2004-12-03 | 2008-01-30 | 先灵公司 | 作为cb1拮抗剂的取代哌嗪 |
| US8361999B2 (en) | 2005-04-04 | 2013-01-29 | Pontificia Universidad Catolica De Chile | Methods of treating cholesterol gallstone disease with ezetimibe |
| DE602006010870D1 (de) * | 2005-06-20 | 2010-01-14 | Schering Corp | Als antagonisten von histamin h3 geeignete piperidinderivate |
| SA06270191B1 (ar) | 2005-06-22 | 2010-03-29 | استرازينيكا ايه بي | مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم |
| MX2008008340A (es) * | 2005-12-21 | 2008-09-03 | Schering Corp | Tratamiento de enfermedad de higado graso no alcoholica usando agentes reductores de colesterol y/o antagonista/agonista inverso de receptor de histamina 3. |
| AR059021A1 (es) | 2006-01-18 | 2008-03-05 | Schering Corp | Moduladores de receptores cannabinoides |
| EP1986489A2 (en) | 2006-02-24 | 2008-11-05 | Schering Corporation | Npc1l1 orthologues |
| TW200811098A (en) | 2006-04-27 | 2008-03-01 | Astrazeneca Ab | Chemical compounds |
| WO2008030382A1 (en) * | 2006-09-05 | 2008-03-13 | Schering Corporation | Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis |
| CN101534818A (zh) * | 2006-09-15 | 2009-09-16 | 先灵公司 | 用于治疗疼痛和脂类代谢疾病的氮杂环丁烷和氮杂环丁酮衍生物 |
| AR062790A1 (es) | 2006-09-15 | 2008-12-03 | Schering Corp | Derivados de azetidina utiles en el tratamiento del dolor, diabetes y trastornos del metabolismo de los lipidos |
| CN101528227A (zh) * | 2006-09-15 | 2009-09-09 | 先灵公司 | 氮杂环丁酮衍生物及其使用方法 |
| WO2008033464A2 (en) * | 2006-09-15 | 2008-03-20 | Schering Corporation | Azetidinone derivatives for the treatment of disorders of the lipid metabolism |
| AU2007294763A1 (en) * | 2006-09-15 | 2008-03-20 | Schering Corporation | Treating pain, diabetes, and lipid metabolism disorders |
| US20080070890A1 (en) * | 2006-09-15 | 2008-03-20 | Burnett Duane A | Spirocyclic Azetidinone Compounds and Methods of Use Thereof |
| CN101541805A (zh) | 2006-09-15 | 2009-09-23 | 先灵公司 | 用于治疗疼痛和脂代射紊乱的氮杂环丁烷和氮杂环丁酮衍生物 |
| US20100197564A1 (en) * | 2007-04-19 | 2010-08-05 | Schering Corporation | Diaryl morpholines as cb1 modulators |
| US8623873B2 (en) | 2007-06-28 | 2014-01-07 | Intervet Inc. | Substituted piperazines as CB1 antagonists |
| US20100286160A1 (en) * | 2007-06-28 | 2010-11-11 | Intervet Inc. | Substituted piperazines as cb1 antagonists |
| CA2754384A1 (en) | 2009-03-06 | 2010-09-10 | Lipideon Biotechnology Ag | Pharmaceutical hypocholesterolemic compositions |
| CN101993403B (zh) | 2009-08-11 | 2012-07-11 | 浙江海正药业股份有限公司 | 氮杂环丁酮类化合物及医药应用 |
| CA2792234C (en) | 2010-03-19 | 2014-05-27 | Pfizer Inc. | 2,3 dihydro-1h-inden-1-yl-2,7-diazaspiro [3.5] nonane derivatives and their use as antagonists or inverse agonists of the ghrelin receptor |
| MX365046B (es) | 2012-05-01 | 2019-05-17 | Althera Life Sciencies Llc | Formulacion de tableta oral que consiste de una combinacion fija de rosuvastatina y ezetimiba para el tratamiento de hiperlipidemia y enfermedades cardiovasculares. |
| CN104496839B (zh) * | 2014-12-03 | 2016-04-20 | 广东东阳光药业有限公司 | 取代环丁烷类神经氨酸酶抑制剂及其使用方法和用途 |
| CN104496838B (zh) * | 2014-12-03 | 2016-04-20 | 广东东阳光药业有限公司 | 取代环丁烷类神经氨酸酶抑制剂及其使用方法和用途 |
| US11401273B2 (en) | 2018-11-20 | 2022-08-02 | Piramal Pharma Limited | Asymmetric synthesis of Azaspiro compounds |
| WO2020191163A1 (en) | 2019-03-20 | 2020-09-24 | Regeneron Pharmaceuticals, Inc. | Treatment of increased lipid levels with sterol regulatory element binding protein cleavage-activating protein (scap) inhibitors |
| JP7574206B2 (ja) | 2019-03-20 | 2024-10-28 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ステロール調節エレメント結合転写因子１（ｓｒｅｂｆ１）阻害剤による上昇した脂質レベルの治療 |
| US20250059187A1 (en) * | 2021-12-22 | 2025-02-20 | The Regents Of The University Of California | Covalently binding inhibitors of g12s, g12d and/or g12e mutants of k-ras gtpase |
| AU2024335101A1 (en) | 2023-08-29 | 2026-02-26 | Regeneron Pharmaceuticals, Inc. | Treatment of muscle disorder with folliculin interacting protein 1 (fnip1) inhibitors and/or folliculin (flcn) inhibitors |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2048080C3 (de) * | 1970-09-30 | 1979-11-29 | Basf Ag, 6700 Ludwigshafen | Verfahren zur Herstellung von N-substituierten 33-disubstituierten ß -Lactamen |
| US4692515A (en) * | 1984-09-24 | 1987-09-08 | Pennwalt Corporation | Adamantane-spirolactams |
| IL89835A0 (en) | 1988-04-11 | 1989-12-15 | Merck & Co Inc | Substituted azetidinones,their preparation and pharmaceutical compositions containing them |
| US4983597A (en) | 1989-08-31 | 1991-01-08 | Merck & Co., Inc. | Beta-lactams as anticholesterolemic agents |
| US5130425A (en) * | 1990-10-12 | 1992-07-14 | American Home Products Corporation | Spiro-lactams and analogs thereof useful as aldose reductase inhibitors |
| ES2107548T3 (es) * | 1991-07-23 | 1997-12-01 | Schering Corp | Compuestos de beta-lactama sustituidos utiles como agentes hipocolesterolemicos y procedimientos para su preparacion. |
-
1994
- 1994-01-13 LT LTIP1764A patent/LT3595B/lt not_active IP Right Cessation
- 1994-01-19 IL IL10836894A patent/IL108368A0/xx unknown
- 1994-01-19 ES ES94907200T patent/ES2155849T3/es not_active Expired - Lifetime
- 1994-01-19 HU HU9502194A patent/HUT72592A/hu unknown
- 1994-01-19 EP EP94907200A patent/EP0681569B1/en not_active Expired - Lifetime
- 1994-01-19 JP JP6517083A patent/JP2719445B2/ja not_active Expired - Fee Related
- 1994-01-19 CN CN94191245A patent/CN1118163A/zh active Pending
- 1994-01-19 NZ NZ261714A patent/NZ261714A/en unknown
- 1994-01-19 CA CA002154257A patent/CA2154257C/en not_active Expired - Fee Related
- 1994-01-19 ZA ZA94386A patent/ZA94386B/xx unknown
- 1994-01-19 PL PL94309978A patent/PL309978A1/xx unknown
- 1994-01-19 AT AT94907200T patent/ATE199899T1/de not_active IP Right Cessation
- 1994-01-19 PT PT94907200T patent/PT681569E/pt unknown
- 1994-01-19 WO PCT/US1994/000421 patent/WO1994017038A1/en not_active Ceased
- 1994-01-19 SK SK911-95A patent/SK91195A3/sk unknown
- 1994-01-19 DE DE69426924T patent/DE69426924T2/de not_active Expired - Lifetime
- 1994-01-19 AU AU60872/94A patent/AU683048B2/en not_active Expired - Fee Related
- 1994-01-19 DK DK94907200T patent/DK0681569T3/da active
- 1994-01-19 SI SI9400022A patent/SI9400022A/sl unknown
- 1994-01-19 FI FI953497A patent/FI953497A0/fi not_active Application Discontinuation
- 1994-01-19 CZ CZ951801A patent/CZ180195A3/cs unknown
- 1994-11-23 EE EE9400394A patent/EE9400394A/xx unknown
-
1995
- 1995-05-25 US US08/449,980 patent/US5698548A/en not_active Expired - Lifetime
- 1995-07-20 NO NO952884A patent/NO952884L/no unknown
- 1995-07-21 KR KR1019950702988A patent/KR960700227A/ko not_active Abandoned
-
2001
- 2001-05-31 GR GR20010400814T patent/GR3035963T3/el not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EE9400394A (et) | 1996-06-17 |
| EP0681569B1 (en) | 2001-03-21 |
| FI953497A7 (fi) | 1995-07-20 |
| HU9502194D0 (en) | 1995-09-28 |
| JP2719445B2 (ja) | 1998-02-25 |
| LT3595B (en) | 1995-12-27 |
| CN1118163A (zh) | 1996-03-06 |
| FI953497A0 (fi) | 1995-07-20 |
| ES2155849T3 (es) | 2001-06-01 |
| AU683048B2 (en) | 1997-10-30 |
| NO952884D0 (no) | 1995-07-20 |
| HUT72592A (en) | 1996-05-28 |
| LTIP1764A (en) | 1995-02-27 |
| CZ180195A3 (en) | 1996-01-17 |
| SI9400022A (en) | 1995-02-28 |
| ZA94386B (en) | 1994-07-19 |
| KR960700227A (ko) | 1996-01-19 |
| EP0681569A1 (en) | 1995-11-15 |
| DE69426924T2 (de) | 2001-08-16 |
| JPH08501110A (ja) | 1996-02-06 |
| IL108368A0 (en) | 1994-04-12 |
| ATE199899T1 (de) | 2001-04-15 |
| CA2154257C (en) | 1999-05-25 |
| GR3035963T3 (en) | 2001-08-31 |
| NZ261714A (en) | 1997-02-24 |
| DE69426924D1 (de) | 2001-04-26 |
| SK91195A3 (en) | 1995-12-06 |
| PT681569E (pt) | 2001-06-29 |
| US5698548A (en) | 1997-12-16 |
| AU6087294A (en) | 1994-08-15 |
| WO1994017038A1 (en) | 1994-08-04 |
| CA2154257A1 (en) | 1994-08-04 |
| DK0681569T3 (da) | 2001-04-23 |
| PL309978A1 (en) | 1995-11-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO952884L (no) | Spirocykloalkyl-substituerte azetidinoner som er anvendbare som hypokolesterolemiske midler | |
| Callens et al. | The contribution of CO33− and CO2− to the ESR spectrum near g= 2 of powdered human tooth enamel | |
| CA2152351C (en) | Combination of a cholesterol biosynthesis inhibitor and a .beta.-lactam cholesterol absorption inhibitor | |
| IE892081L (en) | Cholesterol-Lowering Combination Compositions of Guar Gum¹and Niacin | |
| NO950275L (no) | Kombinasjonsbehandling for osteoporose | |
| BRPI0015947A (pt) | derivado de 6-mercapto-ciclodextrina, uso do mesmo, kit para fornecer bloqueio neuromuscular e sua reversão, composição farmacêutica, e, método para a reversão do bloqueio neuromuscular induzido por medicamento em um paciente. | |
| CA2194876A1 (en) | Bioadhesive-wound healing composition | |
| KR920011471A (ko) | 구강용 치석방지 조성물, 치약 및 치석 방지 방법 | |
| KR880006229A (ko) | 항궤양 활성을 갖는 피리딘 유도체 | |
| EP0976398A3 (en) | Use of 3,4-diphenyl chroman derivatives in the manufacture of a medicament for lowering serum cholesterol levels and inhibiting smooth muscle cell proliferation, restenosis, endometriosis, and uterine fibroid disease | |
| WO2000061604A3 (en) | Pharmaceutical compounds | |
| RU94013440A (ru) | Производные 3-дезоксиолисахаридов, способы их получения и содержащие их фармацевтические композиции | |
| CLARKE-PEARSON et al. | Complications of low-dose heparin prophylaxis in gynecologic oncology surgery | |
| DE69033183D1 (de) | Phosphozucker enthaltende pharmazeutische zubereitung | |
| Toomes et al. | Decortication of the lung | |
| WO2000040225A3 (en) | Inhibition of tnf activity | |
| TW282469B (no) | ||
| EP0990439A4 (en) | BISARYL COMPOUNDS AND ANTICIPATING MEDICAMENTS CONTAINING THEM | |
| CA2118425A1 (en) | Benzothiazolesulfonamide derivative, Method for Preparing the Same, and Use Thereof | |
| JPS5772998A (en) | Novel appamycin derivative | |
| PT912568E (pt) | Imidazopiridinas | |
| HUP9902521A2 (hu) | Trombocitaaggregációt gátló piridinszármazékokat tartalmazó gyógyászati készítmények | |
| AU565187B2 (en) | 2-n-cycloalkylmethyl-3-oxo-5,6-diaryl-as-triazines | |
| EP0304842A3 (en) | Isoprenoid derivatives and anti-ulcer agents containing the same | |
| Furnival et al. | IN‐VITRO STUDIES OF GALLSTONE DISSOLUTION: THE EFFECT OF ADDED HEPARIN IN BILE SALT SOLUTIONS |